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Abstract Introduction: Frontotemporal lobar degeneration–causing mutations in the progranulin (GRN) gene
reduce progranulin protein (PGRN) levels, suggesting that restoring PGRN in mutation carriers may
be therapeutic. Nimodipine, a Food and Drug Administration–approved blood-brain barrier-pene-
trant calcium channel blocker, increased PGRN levels in PGRN-deficient murine models. We sought
to assess safety and tolerability of oral nimodipine in human GRN mutation carriers.
Methods: We performed an open-label, 8-week, dose-finding, phase 1 clinical trial in eightGRNmu-
tation carriers to assess the safety and tolerability of nimodipine and assayed fluid and radiologic
markers to investigate therapeutic endpoints.
Results: There were no serious adverse events; however, PGRN concentrations (cerebrospinal fluid
and plasma) did not change significantly following treatment (percent changes of 25.2 6 10.9% in
plasma and210.26 7.8% in cerebrospinal fluid). Measurable atrophy within the left middle frontal
gyrus was observed over an 8-week period.
Discussion: While well tolerated, nimodipine treatment did not alter PGRN concentrations or
secondary outcomes.
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1. Introduction
Mutations in the progranulin gene (GRN) are a common
cause of inherited frontotemporal dementia (FTD).GRNmu-
tations cause haploinsufficiency, with only one functional
copy of the gene remaining. Progranulin protein (PGRN)
levels are less than 50% from birth [1–3]. Thus, therapeutic
approaches have focused on increasing PGRN levels, either
by increasing transcription from the normal allele [4,5] or
by modulating posttranslational mechanisms [6,7].
Promising preclinical data in heterozygousGrnmice sug-
gested that nimodipine might restore PGRN levels in hu-
mans with GRN mutations. As PGRN levels are stable
over both short and long periods (1 week to 2 years) in
GRN mutation carriers [8] as well as various disease and
control populations [9], PGRN levels alone are suitable end-
points for trials. We tested the effects of modulators of cal-
cium homeostasis on PGRN levels in cultured cells and
found that reducing intracellular calcium by blocking cal-
cium channels increased PGRN secretion. We focused on ni-
modipine, a Food and Drug Administration–approved
L-type calcium channel blocker that crosses the blood-
brain barrier, as it is relatively well tolerated and, in a
placebo-controlled trial, it improved overall status and
cognitive function in patients with dementia [10].
We report the effects of nimodipine on PGRN levels in
plasma and central nervous system tissues in correlative
studies on animals and humans carrying GRN mutations. In
a phase 1, 8-week open-label clinical trial, we sought to deter-
mine the safety and tolerability of oral nimodipine treatment in
GRN mutation carriers and the best dose of nimodipine for
long-term efficacy studies. As secondary objectives, we inves-
tigated the effects of nimodipine on PGRN levels in plasma
and cerebrospinal fluid (CSF), a subset of inflammatory and
neurodegeneration-associated proteins, and in brain volumes.
2. Methods
2.1. Study oversight
This study was approved under local institutional review
board’s supervision, registered at ClinicalTrials.gov
(NCT01835665). Informed consent was obtained from pa-
tients and, when applicable, caregivers.
2.2. Study design and enrollment
The target enrollment was eight asymptomatic and/or
symptomatic carriers of known FTD-causing GRNmutations
(Supplementary Fig. 2). Participants were required to be
aware of their mutation status before screening. Participants
were enrolled fromMarch 2013 until January 2015. Inclusion
and exclusion criteria are listed in Supplementary Materials.
Because nimodipine is a Food and Drug Administration–
approved drug at a dose of 360 mg per day, we chose a titra-
tion to 360 mg or maximum tolerated dose. Nimodipine was
titrated every week as follows: 30 mg orally TID, 60 mg
TID, 90 mg TID, and 90 mg QID and maintained at this
dose for 4 weeks. All subjects attempted to titrate to the
full 360 mg per day dose (Supplementary Fig. 3).
2.3. Outcomes
Primary outcomes were safety and tolerability of
nimodipine and identification of the optimal nimodipine
dose for long-term efficacy studies in GRN mutation
carriers. Safety was measured by the number of treatment
emergent adverse events (listed by detailed MedDRA
term [www.meddra.org]), routine clinical, laboratory, and
electrocardiogram assessments. Secondary outcomes were
change from baseline concentration of plasma PGRN or
CSF PGRN, plasma PGRN-related inflammatory markers
(c-reactive protein [CRP], erythrocyte sedimentation rate
[ESR]), CSF neurodegeneration proteins (neurofilament
light chain [NfL], amyloid b 42 [Ab42], tau), blood and
CSF cytokines (interleukin-10 [IL-10], IL-2, IL-6, IL-8,
and tumor necrosis factor a [TNFa]), and volumetric mag-
netic resonance imaging (MRI).
2.4. Plasma and CSF sampling and analysis
PGRN was measured by A&G Pharma (Columbia, MD)
using a proprietary enzyme-linked immunosorbent assay
that detects full-length PGRN. TNFawasmeasured by Quan-
terix (Lexington, MA). Tau, phospho-tau181, and Ab42 levels
were analyzed using the xMAP multiplex immunoassay/Lu-
minex analyzer (INNO-BIA AlzBio3; Fujirebio). NfL levels
were measured using the UmanDiagnostics kit (Umea, Swe-
den). Proinflammatory cytokines were measured in plasma
and CSF using a V-PLEX human proinflammatory 10-Plex
kit from Meso Scale Discovery (Rockville, MD). Nonpara-
metric measures (Mann-Whitney U) were used to compare
mean baseline versus 8-week or early termination values of
the secondary clinical and laboratory measures.
2.5. Brain imaging
MRI was performed at screening and completion of the
study using a 3T Siemens scanner [11]. MP-RAGE scans
for both time points for a given subject were registered to
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Table 1
Characteristics of study participants
Clinical Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 Subject 6 Subject 7 Subject 8 Mean
Clinical phenotype (clinicians’
impression)
nfvPPA Asymptomatic Asymptomatic bvFTD bvFTD Asymptomatic bvFTD Asymptomatic -
CDR-SB 0 0.5 0 12 4 0 2 0 2.3
MMSE 29 29 30 - 22 30 25 30 27.9
Completed 8 weeks? Yes Yes Yes Yes Yes Yes Yes No -
Max dose achieved (mg) 360 360 360 360 180–270 360 360 180 -
Plasma Mean 6 SEM
GRN ng/mL, (% change) 1.1 (21) 1.4 (19) 212.6 (253) 20.2 (22) 4.9 (23) 21.5 (216) 23.4 (227) - 21.47 6 2.1 (25.2 6 10.9)
ESRmm/hour, (% change) 2 (40) nd 0 (0) 0 (0) 19 (91) 24 (500) 25 (231) - 6 6 4.3 (99.9 6 81.8)
CRP mg/L, (% change) 0.4 (14) 20.1 (21) 1.2 (92) 21.7 (39) 6.8 (145) 5.9 (590) 0.1 (6) - 1.8 6 1.2 (115.4 6 62.5)
CSF
GRN ng/mL, (% change) 20.07 (213) 0.06 (27) 20.15 (218) 20.2 (227) 20.28 (241) 0.06 (15) 20.05 (212) 20.08 (217) 20.09 6 0.04 (210.7 6 7.8)
NfL pg/mL, (% change) 211.8 (5) 239.5 (212) 27.4 (0) 750.6 (5) 2654.5 (28) 71.4 (9) 2499.9 (25) 277.9 (27) 230.68 6 151.8 (21.4 6 2.5)
Ab42 pg/mL, (% change) 28.7 (21) 281.6 (215) 76.8 (11) 19.7 (4) 246.3 (214) 235.4 (26) 258.3 (212) 2103.9 (219) 229.70 6 20.5 (26.5 6 3.6)
Tau pg/mL, (% change) 4.2 (7) 24.2 (214) 20.4 (21) 25.8 (25) 10.0 (12) 26.7 (216) 2.2 (23) 2.0 (5) 3.59 6 3.7 (1.9 6 4.8)
P-tau pg/mL, (% change) 21.7 (27) 5.8 (31) 20.8 (23) 23.0 (213) 2.0 (17) 28.0 (234) 7.8 (89) 1.6 (13) 0.48 6 1.8 (11.6 6 13.1)
IL-10 pg/mL, (% change) 0.03 (6) 0.001 (21) 0.005 (25) 0.01 (11) 20.01 (215) - 0.003 (4) 0.04 (65) 0.00 6 0.1 (9.1 6 9.8)
IL-2 pg/mL, (% change) 0.01 (10) 0.01 (31) 0.03 (62) 20.02 (233) 0 (9) - 0.03 (36) 0.01 (14) 0.01 6 0.01 (18.5 6 11.2)
IL-6 pg/mL, (% change) 0.11 (6) 20.15 (211) 20.04 (23) 0.07 (7) 0.14 (13) - 0.11 (16) 0.06 (8) 0.04 6 0.04 (5.1 6 3.5)
IL-8 pg/mL, (% change) 3.82 (5) 1.24 (4) 20.38 (21) 6.74 (9) 4.65 (11) - 21.72 (26) 20.16 (0) 2.0 6 1.17 (3.1 6 2.2)
TNFa pg/mL, (% change) 0.00 (0) 20.05 (238) 0.02 (14) 20.07 (216) 0.04 (42) - 0.00 (21) 0.01 (9) 0.01 6 0.02 (1.4 6 9.4)
Abbreviations: Ab42, amyloid b; CDR-SB, Clinical Dementia Rating–sum of boxes; CSF, cerebrospinal fluid; GRN, progranulin; CRP, c-reactive protein; ESR, erythrocyte sedimentation rate; MMSE, Mini–
Mental State Examination; nd, not determined; NfL, neurofilament light chain; P-tau, phospho-tau; TNFa, tumor necrosis factor a.
NOTE. Age and gender were not shown to maintain participant confidentiality.
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one another using the serial longitudinal anatomical MRI
package in SPM12 [12], and the procedures outlined else-
where [13].
3. Results
3.1. Preclinical studies
Cultured cellular models revealed that cytosolic calcium
levels affected the secreted PGRN levels (Supplementary
Fig. 1). Two-week treatment with nimodipine elevated hip-
pocampal PGRN levels in both wild-type (P , .001) and
Grn1/– mice (P , .05) compared to vehicle-treated mice
(Supplementary Fig. 1).
3.2. Demographics
Eight GRN mutation carriers were enrolled in the trial
(Table 1), with a median age of 57.3 years; 50% were
male. They included three behavioral-variant FTD (bvFTD),
one nonfluent-variant primary progressive aphasia
(nfvPPA), and four asymptomatic individuals. One self-
reported asymptomatic participant had a 0.5 in judgment
on the Clinical Dementia Rating–sum of boxes (CDR-SB)
and thus fit into the classification of normal with concerns.
3.3. Safety and tolerability
Two of the eight participants (25%) were unable to titrate
to the maximum dose of 360 mg per day (Table 1). One
participant discontinued treatment early at week 5 due to
dizziness, palpitations, and malaise. Another discontinued
due to edema. There were no serious adverse events.
Forty-three adverse events were reported; the most common
included edema (12 reports), headache (3), and dizziness (3).
There were also two reports of arrhythmia and lassitude.
There were single reports of upper respiratory infection,
flu-like symptoms, syncope, redness on legs, depression,
insomnia, worsening of asthma, and urinary tract infection.
3.4. Fluid biomarkers
PGRN concentrations, in plasma and CSF, did not change
from baseline after nimodipine treatment (percent changes
of 25.2 6 10.9% [mean 6 standard error mean] in plasma
and 210.2 6 7.8% in CSF) (Table 1 and Fig. 1A and 1B).
CSF levels of three neurodegenerative disease–associated
proteins, NfL, Ab42, and tau (both total tau and phospho-tau)
did not change significantly after nimodipine treatment
(Table 1). Levels of CSF NfL (P 5 .0002, Mann-Whitney
U) and tau (P 5 .0002, Mann-Whitney U) at baseline corre-
lated with disease severity as measured by CDR-SB, with the
highest levels of NfL and tau observed in subjects with the
highest CDR-SB score (Fig. 1C and 1D).
Of 10 cytokines measured in CSF, five were detectable
(IL-10, IL-2, IL-6, IL-8, and TNFa), and none exhibited a sig-
nificant change following nimodipine treatment (Table 1).
3.5. Volumetric MRI
Longitudinal structural MRI differences were determined
by performing a one-sample t-test on the longitudinal Jaco-
bian gray matter change maps. Six subjects were analyzed
(mean age 5 56.2 years, range 32.5–69.0; 4 females;
mean interscan interval 5 50.7 days, range 29–70). The
resultant map was corrected with a joint height/extent
threshold of P , .001 (no significant reductions were de-
tected at a more stringent threshold of P , .05, family-
wise error corrected). There was one significant cluster of
gray matter loss in the left middle frontal gyrus. The rate
of change in this cluster revealed that the effect was driven
by four subjects with annualized rates of gray matter loss be-
tween 1% and 2% (Fig. 1).
4. Discussion
PGRN deficiency causes FTD; therefore, treatments that
restore PGRN levels are of high therapeutic interest. We
found that oral nimodipine increased mouse hippocampal
PGRN concentrations but failed to increase human PGRN
levels in plasma and CSF. In an 8-week, open-label trial,
nimodipine was safe and well tolerated in GRN mutation
carriers, but no effects of nimodipine were noted on second-
ary outcome measures, including concentrations of PGRN in
blood and CSF, CSF NfL, CSF Ab42, CSF total tau, CSF
phospho-tau, plasma ESR, plasma CRP, or CSF cytokines
(IL-10, IL-2, IL-6, IL-8, and TNFa). Although there were
no clear effects on volumetric MRI measurements by nimo-
dipine, there was volume loss noted in severely affected pa-
tients. Reasons for the discrepancy between rodents and
humans are unknown and may be related to many factors,
including exposure, dose, timing, and interspecies difference
in responsiveness.
Of the six participants with MRIs conducted before and
after treatment, three were asymptomatic and three were
symptomatic. The most severely affected cases displayed
the greatest decrease in volume over the trial period; a
change that would extrapolate to a 1%–2% loss in the
volume of the left frontal region annually, if constant.
This rate is slightly less than reported for whole-brain
atrophy in a comparably sized group of GRN mutation
carriers assessed with MRI scans over 2 years [14]. Inter-
mediate volume loss was observed in a mildly symptom-
atic individual and in an asymptomatic individual with a
score of 0.5 on CDR-SB for judgment. The two asymp-
tomatic cases revealed no change in brain volume. Given
that nimodipine did not raise levels of PGRN, we propose
this rate of decline may be comparable to untreated GRN
mutation carriers. However, we cannot exclude a contribu-
tion of volume loss from treatment with nimodipine. If
this rate of volume loss is confirmed in a larger cohort
of mutation carriers, slowing or reversal of regional gray
matter loss could be a viable endpoint in future FTD-GRN
clinical trials.
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This is the second reported trial to be completed in GRN
mutation carriers [7]. There are a number of therapeutic tar-
gets in the development pipeline intended for GRNmutation
carriers, and this study provides a framework for future
bench-to-bedside proof of mechanism studies for FTD-
GRN.
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RESEARCH IN CONTEXT
1. Systematic review: The authors reviewed the litera-
ture using traditional (e.g., PubMed) sources. Hetero-
zygous loss of function mutations in the progranulin
gene (GRN) lead to frontotemporal dementia (FTD)
through decreased production of the normal progra-
nulin protein (PGRN). Therapeutic approaches
have focused on finding novel compounds that in-
crease PGRN levels. In murine model systems, cal-
cium channel blockers were discovered to increase
PGRN levels. We launched a phase 1 trial of nimodi-
pine inGRNmutation carriers to test safety and toler-
ability.
2 Interpretation: Nimodipine was safe and well toler-
ated but is unlikely to provide therapeutic benefit in
GRN FTD.
3. Future directions: This trial demonstrated that a
nimble, small-scale trial could arise entirely from,
and be contained within, an academic center. From
the initial target identification to the execution of
human trials, this trial provides a framework for
future bench-to-bedside proof of mechanism studies
in FTD.
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